Razlika med povprečno spremembo od izhodišča do 26 tedna/ zaključka (Zadnje opazovanje preneseno vnaprej; Last Observation Carried Forward - LOCF) je bila statistično pomembna (UPDRS, deli I- III: za razagilin 1 mg v primerjavi s placebom - 4, 2, 95 % CI [ - 5, 7, - 2, 7 ]; p < 0. 0001; za razagilin 2 mg v primerjavi s placebom - 3, 6, 95 % CI [ - 5, 0, - 2, 1 ]; p < 0. 0001; UPDRS motorični, del II: za razagilin 1 mg v primerjavi s placebom - 2, 7, 95 % CI [ - 3, 87, - 1, 55 ]; p < 0. 0001; za razagilin 2 mg v primerjavi s placebom - 1, 68, 95 % CI [ - 2, 85, - 0, 51 ]; p = 0. 0050).
The difference between the mean change from baseline to week 26/ termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95 % CI [ -5.7, -2.7 ]; p < 0.0001; for rasagiline 2 mg compared to placebo -3.6, 95 % CI [ -5.0, -2.1 ]; p < 0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95 % CI [ -3.87, -1.55 ], p < 0.0001; for rasagiline 2 mg compared to placebo -1.68, 95 % CI [ -2.85, -0.51 ], p=0.0050).